Results presented at the American Heart Association Scientific Sessions 2026 show that pelacarsen, an investigational drug that lowers lipoprotein(a), reduced its target but did not reduce heart attacks and strokes. An anti-inflammatory heart drug from another company also failed to meet expectations this week.
High lipoprotein(a) remains an important, largely inherited risk marker for cardiovascular disease. The findings show that lowering a biomarker does not always translate into fewer clinical events.
Source: Medscape (AHA 2026)















